SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Transgene Biotek Ltd

BSE: 526139 NSE: ISIN: INE773D01018
  |   Sector:  Miscellaneous   |   Industry:  Business Support

Snapshot

Q.1 Is Transgene Biotek Ltd a good quality company?
Transgene Biotek Ltd is a quality company, based on a 10 year financial track record .
Q.2 Is Transgene Biotek Ltd undervalued or overvalued?
Transgene Biotek Ltd appears Overvalued , as its key valuation ratios are below with their past averages.
Q.3 Is Transgene Biotek Ltd a good buy now?
Transgene Biotek Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall . However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Gross Profit margin of Transgene Biotek Ltd?
Transgene Biotek Ltd Gross profit margin which is the profit after deduction of direct costs, is -223.6% for FY-2025 , which is below its 5 year median of 0% , indicating decreasing margins.
Q.2 Operating Profit Margin of Transgene Biotek Ltd?
Transgene Biotek Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -430.19% for FY-2025 , which is below its 5 year median of 0% indicating decreasing margins.
Q.3 Net Profit Margin of Transgene Biotek Ltd?
Transgene Biotek Ltd Net Profit Margin is -259.34% for FY-2025 , is below with its 5 year median of 0%, indicating decreasing margins.
Q.4 Return on Asset of Transgene Biotek Ltd?
Transgene Biotek Ltd Return on Asset is -2.03(x), which is below its 5 year historical median of 0(x), indicating deteriorated asset utilization efficiency.
Q.5 Return on Equity (ROE) of Transgene Biotek Ltd?
Transgene Biotek Ltd Return on equity is 0% for FY-2025 , which is in line with its historical median of 0%, indicating the business is making similar use of its shareholders capital.
Q.6 Return on capital employed (ROCE) of Transgene Biotek Ltd?
Transgene Biotek Ltd Return on capital employed is -6.11% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation .
Q.7 Cash conversion cycle of Transgene Biotek Ltd?
Transgene Biotek Ltd Cash conversion cycle is -564 , below its historical median of 0 , indicating improved working capital management. However, you need to compare this with its peers in the industry.
Q.8 Debt to Equity ratio of Transgene Biotek Ltd?
Transgene Biotek Ltd Debt-to-Equity ratio is -1.92 , which is lower with the industry average of 0 , indicating lower debt levels in the industry.
Q.9 Debt to cash flow from operations of Transgene Biotek Ltd?
Transgene Biotek Ltd Debt to cash flow from operations is 12.14 , which is at a unhealthy level, indicating the business is not able to service its debt comfortably.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Transgene Biotek Ltd?
Promoters hold 23.64% of the Transgene Biotek Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Transgene Biotek Ltd vs industry peers?
Transgene Biotek Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 19.49% , indicating slower growth and losing its market share.

Valuation & price assessment

Q.1 Stock return of Transgene Biotek Ltd over the last decade?
Over the last 9 years, the stock has delivered a CAGR of 3.4% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 3.4% -14.3% 1.8% -27.4%
Q.3 Valuation ratios of Transgene Biotek Ltd vs historical?
The current P/E is similar that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - 0.00 29.41
Price to Book -2.3 3.06 2.54
Price to Sales 85.44 0.00 4.88
EV to EBITDA -48.06 0.00 11.31

Check more companies

1. Prime Focus
2. Sagility
3. Syngene Internation.
4. International Gemolo
5. Indegene
6. NESCO
7. Latent View Analytic
8. Just Dial
9. CMS Info Systems
10. Sun Pharma Adv. Res
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×